Skip to main content

Advertisement

SpringerLink
Log in

Clinical significance of estrogen receptor β in breast cancer

  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Ever since the estrogen receptor (ER) β was discovered in 1996, we have been trying to determine its value as a prognostic and/or predictive factor in breast cancer and its potential as a novel target for pharmacological intervention. Recent progress in cellular experiments has shown that ERβ works as counter partner of ERα through inhibition of the transactivating function of ERα by heterodimerization, distinct regulation on several specific promoters by ERα or ERβ, and ERβ-specific regulated genes which are probably related to its anti-proliferative properties. Accumulated data from protein studies in breast cancer tissues indicate that positive expression of ERβ appears to correlate with a favorable prognosis. Although the number of studies is small, a positive response to tamoxifen treatment is observed in both ERα- and ERβ-positive populations. The significance of ERβ2/cx, a splicing variant of ERβ, remains controversial and needs to be analyzed in further studies. We postulate that a combined evaluation of ERβcx with progesterone receptor may help the stratification of ERα-positive breast cancer. Epidemiological studies of hormone replacement therapy and isoflavone (genistein) consumption indicate the possible contribution of ERβ-specific signaling in breast cancer prevention. A selective estrogen receptor modulator, which works as an antagonist of ERα and an agonist of ERβ, may be a promising chemo-preventive treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Adlercreutz H (2002) Phyto-oestrogens and cancer. Lancet Oncol 3:364–373

    Article  PubMed  Google Scholar 

  2. Balfe P, McCann A, McGoldrick A, McAllister K, Kennedy M, Dervan P, Kerin MJ (2004) Estrogen receptor alpha and beta profiling in human breast cancer. Eur J Surg Oncol 30:469–474

    Article  PubMed  CAS  Google Scholar 

  3. Beral V, Banks E, Reeves G (2002) Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 360:942–944

    Article  PubMed  Google Scholar 

  4. Cappelletti V, Celio L, Bajetta E, Allevi A, Longarini R, Miodini P, Villa R, Fabbri A, Mariani L, Giovanazzi R, Galante E, Greco M, Grazia Daidone M (2004) Prospective evaluation of estrogen receptor-beta in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients. Endocr Relat Cancer 11:761–770

    Article  PubMed  CAS  Google Scholar 

  5. Chang HG, Kim SJ, Chung KW, Noh DY, Kwon Y, Lee ES, Kang HS (2005) Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene. J Mol Med 83:132–139

    Article  PubMed  CAS  Google Scholar 

  6. Cowley SM, Parker MG (1999) A comparison of transcriptional activation by ER alpha and ER beta. J Steroid Biochem Mol Biol 69:165–175

    Article  PubMed  CAS  Google Scholar 

  7. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjold M, Gustafsson JA (1997) Human estrogen receptor beta-gene structure, chromosomal localization and expression pattern. J Clin Endocrinol Metab 82:4258–4265

    Article  PubMed  CAS  Google Scholar 

  8. Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, Lavaill R, Mollevi C, Warner M, Gustafsson JA, Rochefort H (2004) Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 10:5769–5776

    Article  PubMed  CAS  Google Scholar 

  9. Fuqua SA, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK, Clark GM, Allred DC (2003) Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 63:2434–2439

    PubMed  CAS  Google Scholar 

  10. Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, Chambon P (1986) Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320:134–139

    Article  PubMed  CAS  Google Scholar 

  11. Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J (1986) Sequence and expression of human estrogen receptor complementary DNA. Science 231:1150–1154

    Article  PubMed  CAS  Google Scholar 

  12. Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA (2004) Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 10:7490–7499

    Article  PubMed  CAS  Google Scholar 

  13. Jensen EV, Jacobsen HI (1962) Basic guides to the mechanism of estrogen action. Rec Prog Horm Res 18:387–414

    CAS  Google Scholar 

  14. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925–5930

    Article  PubMed  CAS  Google Scholar 

  15. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139:4252–4263

    Article  PubMed  CAS  Google Scholar 

  16. Lindberg MK, Moverare S, Skrtic S, Gao H, Dahlman-Wright K, Gustafsson JA, Ohlsson C (2003) Estrogen receptor (ER)-beta reduces ERalpha-regulated gene transcription, supporting a “ying yang” relationship between ERalpha and ERbeta in mice. Mol Endocrinol 17:203–208

    Article  PubMed  CAS  Google Scholar 

  17. Mann S, Laucirica R, Carlson N, Younes PS, Ali N, Younes A, Li Y, Younes M (2001) Estrogen receptor beta expression in invasive breast cancer. Hum Pathol 32:113–118

    Article  PubMed  CAS  Google Scholar 

  18. Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su JL, Kliewer SA, Lehmann JM, Willson TM (1998) Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 247:75–78

    Article  PubMed  CAS  Google Scholar 

  19. Murphy LC, Leygue E, Niu Y, Snell L, Ho SM, Watson PH (2002) Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. Br J Cancer 87:1411–1416

    Article  PubMed  CAS  Google Scholar 

  20. Myers E, Fleming FJ, Crotty TB, Kelly G, McDermott EW, O’higgins NJ, Hill AD, Young LS (2004) Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer. Br J Cancer 91:1687–1693

    PubMed  CAS  Google Scholar 

  21. Nakopoulou L, Lazaris AC, Panayotopoulou EG, Giannopoulou I, Givalos N, Markaki S, Keramopoulos A (2004) The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol 57:523–528

    Article  PubMed  CAS  Google Scholar 

  22. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA (2001) Mechanisms of estrogen action. Physiol Rev 81:1535–1565

    PubMed  CAS  Google Scholar 

  23. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M (1998) Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of oestrogen action in human. Nucleic Acids Res 26:3505–3512

    Article  PubMed  CAS  Google Scholar 

  24. Omoto Y, Inoue S, Ogawa S, Toyama T, Yamashita H, Muramatsu M, Kobayashi S, Iwase H (2001) Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Lett 163:207–212

    Article  PubMed  CAS  Google Scholar 

  25. Omoto Y, Kobayashi S, Inoue S, Ogawa S, Toyama T, Yamashita H, Muramatsu M, Gustafsson JA, Iwase H (2002) Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur J Cancer 38:380–386

    Article  PubMed  CAS  Google Scholar 

  26. Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y, Hayashi S (2003) Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene 22:5011–5020

    Article  PubMed  CAS  Google Scholar 

  27. O’Neill PA, Davies MP, Shaaban AM, Innes H, Torevell A, Sibson DR, Foster CS (2004) Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in tamoxifen-treated post-menopausal breast cancers. Br J Cancer 91:1694–1702

    PubMed  CAS  Google Scholar 

  28. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS (1997) Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277:1508–1510

    Article  PubMed  CAS  Google Scholar 

  29. Palmieri C, Cheng GJ, Saji S, Zelada-Hedman M, Warri A, Weihua Z, Van Noorden S, Wahlstrom T, Coombes RC, Warner M, Gustafsson JA (2002) Estrogen receptor beta in breast cancer. Endocr Relat Cancer 9:1–13

    Article  PubMed  CAS  Google Scholar 

  30. Palmieri C, Lam EW, Mansi J, MacDonald C, Shousha S, Madden P, Omoto Y, Sunters A, Warner M, Gustafsson JA, Coombes RC (2004) The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res 10:2421–2428

    Article  PubMed  CAS  Google Scholar 

  31. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H (2001) Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61:2537–2541

    PubMed  CAS  Google Scholar 

  32. Saji S, Omoto Y, Shimizu C, Warner M, Hayashi Y, Horiguchi S, Watanabe T, Hayashi S, Gustafsson JA, Toi M (2002) Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Cancer Res 62:4849–4853

    PubMed  CAS  Google Scholar 

  33. Shaaban AM, O’Neill PA, Davies MP, Sibson R, West CR, Smith PH, Foster CS (2003) Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol 27:1502–1512

    Article  PubMed  Google Scholar 

  34. Skliris GP, Munot K, Bell SM, Carder PJ, Lane S, Horgan K, Lansdown MR, Parkes AT, Hanby AM, Markham AF, Speirs V (2003) Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 201:213–220

    Article  PubMed  CAS  Google Scholar 

  35. Speirs V, Malone C, Walton DS, Kerin MJ, Atkin SL (1999) Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res 59:5421–5424

    PubMed  CAS  Google Scholar 

  36. Speirs V, Skliris GP, Burdall SE, Carder PJ (2002) Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J Clin Pathol 55:371–374

    PubMed  CAS  Google Scholar 

  37. Speirs V, Carder PJ, Lane S, Dodwell D, Lansdown MR, Hanby AM (2004) Oestrogen receptor beta: what it means for patients with breast cancer. Lancet Oncol 5:174–181

    Article  PubMed  CAS  Google Scholar 

  38. Stossi F, Barnett DH, Frasor J, Komm B, Lyttle CR, Katzenellenbogen BS (2004) Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: distinct and common target genes for these receptors. Endocrinology 145:3473–3486

    Article  PubMed  CAS  Google Scholar 

  39. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA (2004) Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 101:1566–1571

    Article  PubMed  CAS  Google Scholar 

  40. Taylor AH, Al-Azzawi F (2000) Immunolocalisation of oestrogen receptor beta in human tissues. J Mol Endocrinol 24:145–155

    Article  PubMed  CAS  Google Scholar 

  41. Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S, Japan Public Health Center-Based Prospective Study on Cancer Cardiovascular Diseases Group (2003) Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst 95:906–913

    Google Scholar 

  42. Yamamoto Y, Shibata J, Yonekura K, Sato K, Hashimoto A, Aoyagi Y, Wierzba K, Yano S, Asao T, Buzdar AU, Terada T (2005) TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect. Clin Cancer Res 11:315–322

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery and Breast Oncology, Department of Clinical Trials and Research, Tokyo Metropolitan Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, 113-8677, Tokyo, Japan

    Shigehira Saji, Makiko Hirose & Masakazu Toi

Authors
  1. Shigehira Saji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Makiko Hirose
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masakazu Toi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shigehira Saji.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saji, S., Hirose, M. & Toi, M. Clinical significance of estrogen receptor β in breast cancer. Cancer Chemother Pharmacol 56 (Suppl 1), 21–26 (2005). https://doi.org/10.1007/s00280-005-0107-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-005-0107-3

Keywords

Search

Navigation